Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC17H21N3O2 |
InChIKeyUVUZILRDAIQCNT-UHFFFAOYSA-N |
CAS Registry2702280-89-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | US | 14 May 2020 |